Примери за използване на Decreased susceptibility на Английски и техните преводи на Български
{-}
-
Medicine
-
Colloquial
-
Official
-
Ecclesiastic
-
Ecclesiastic
-
Computer
Decreased susceptibility varied from approximately 10-50%.
Resistance Clinical isolates with decreased susceptibility to posaconazole have been identified.
Decreased susceptibility in Acinetobacter baumannii has been attributed to the overexpression of the AdeABC efflux pump.
Resistance to tiamulin may be associated with decreased susceptibility to other pleuromutilins.
Strains with decreased susceptibility have been reported in some countries in the EU with a frequency higher than 10%.
Calcium is necessary for optimal resistance to sodium toxicity and decreased susceptibility to botrytis.
HIV-1 isolates with decreased susceptibility to amprenavir have been selected during in vitro serial passage experiments.
Resistance to lincomycin can readily develop in B. hyodysenteriae andmost of the isolates studied show decreased susceptibility in vitro.
Clinical isolates(n=5) with decreased susceptibility to zidovudine, lamivudine, or nevirapine remain fully susceptible to nelfinavir in vitro.
Resistance in cell culture: relative to wild-type HBV, LVDr viruses containing rtM204V andrtL180M substitutions within the reverse transcriptase exhibit 8-fold decreased susceptibility to entecavir.
Decreased susceptibility in both groups has been attributed to the overexpression of the non-specific AcrAB multi-drug efflux pump.
Relative to wild-type HBV, LVDr viruses containing rtM204V andrtL180M substitutions within the reverse transcriptase exhibit 8-fold decreased susceptibility to entecavir.
The decreased susceptibility to darunavir of the emerging viruses in the selection experiment could not be explained by the emergence of these protease mutations.
Isolates with baseline FC≤ 10 are susceptible; isolates with FC>10 to 40 have decreased susceptibility; isolates with FC> 40 are resistant(see Clinical results).
The decreased susceptibility to darunavir of the emerging viruses in the selection experiment could not be explained by the emergence of these protease mutations.
Isolates with baseline fold change of> 0 to 3 are considered susceptible; isolates with>3 to 10 fold changes have decreased susceptibility; isolates with> 10 fold changes are resistant.
Decreased susceptibility to ibalizumab was a finding in the majority of patients who experienced virologic failure up to week 24 in the pivotal study.
An HIV isolate obtained from a patient receiving saquinavir therapy showed decreased susceptibility to saquinavir(7- fold) but did not demonstrate a concordant decrease in susceptibility to nelfinavir.
Rates of decreased susceptibility of E. coli to ciprofloxacin based on an epidemiological cut-off of 0.06 mg/l were 19.3% in 1999-2000 and 33.5% in 2005-6.
Conversely, following ritonavir therapy, 6 of 7 clinical isolates with decreased ritonavir susceptibility(8- to 113-fold) in vitro compared to baseline also exhibited decreased susceptibility to nelfinavir in vitro(5- to 40 fold).
Literature data indicate that decreased susceptibility in B. hyodysenteriae could be overcome to some extent by the high concentrations attained locally.
Tipranavir maintains significant antiviral activity(< 4-fold resistance)against the majority of HIV-1 clinical isolates showing post-treatment decreased susceptibility to the currently approved protease inhibitors: amprenavir, atazanavir, indinavir, lopinavir, ritonavir.
Also, information as to widespread decreased susceptibility in B. hyodysenteriae and as to the bimodal distribution in E. coli should be added to section 5.1.
This observed decrease of susceptibility could either be explained by methodological factors, orit could reflect a true emergence of decreased susceptibility, that could be related to the use of enrofloxacin in rabbits or other animal species.
Decreased susceptibility to ibalizumab does not alter susceptibility to other approved agents and does not result in the selection of CD4-independent viral isolates.
Tipranavir resistant viruses which emerge in vitro from wild-type HIV-1 show decreased susceptibility to the protease inhibitors amprenavir, atazanavir, indinavir, lopinavir, nelfinavir and ritonavir but remain sensitive to saquinavir.
In 1 virologic failure of the PREZISTA/ritonavir group, 1 developing NRTI RAM at position 184 was identified,which was associated with a decreased susceptibility to emtricitabine included in the background regimen.
Viruses selected in these conditions and showing decreased susceptibility to darunavir(range: 23-50fold) harboured 2 to 4 amino acid substitutions in the protease gene.
Caution on the choice of antibiotic agent and dose should be taken when treating patients with late-onset ventilator-associated pneumonia(> 5 days hospitalisation) andin other nosocomial pneumonia cases where pathogens with decreased susceptibility are suspected or confirmed, such as Pseudomonas spp.
Viruses selected in these conditions and showing decreased susceptibility to darunavir(range: 23-50-fold) harboured 2 to 4 amino acid substitutions in the protease gene.